Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs

Joseph E. Harrington, Edbert B. Hsu

Research output: Contribution to journalArticle

Abstract

To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalJournal of health economics
Volume29
Issue number3
DOIs
StatePublished - May 2010

Keywords

  • Pandemic
  • Pharmaceutical products
  • Pricing

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs'. Together they form a unique fingerprint.

  • Cite this